drugset
drugset / Trial / NCT03920254

TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study

NCT03920254 ↗

Phase 2/3 Terminated 46 enrolled Theravance Biopharma
Non-randomizedParallel-groupQuadruple-blindTreatment

Summary

A 3-Year Multi-Center, Long-Term Safety (LTS) Study to Evaluate the Safety and Tolerability of TD-1473 in Subjects with Ulcerative Colitis who have participated in the Maintenance Study of Protocol 0157

Timeline

Start
2020-07-23
Primary completion
2021-10-27
Completion
2021-10-27

Outcome

Outcome not reported

Stopped: “Stopped early due to company decision. Company decision based on interim analysis results in TD-1473-0157.”

Drugs

EvaluationDrugModalityDoseRoute
Subject IZENCITINIB Small molecule — Oral

Indications

ulcerative colitis